Literature DB >> 18230552

Safety of prolonged high-dose levofloxacin therapy for bone infections.

E Senneville1, J Poissy, L Legout, C Dehecq, C Loïez, M Valette, E Beltrand, M Caillaux, Y Mouton, H Migaud, Y Yazdanpanah.   

Abstract

The records of 84 patients with bone infections treated with high-dose levofloxacin (i.e. 0.75-1g daily) for more than 4 weeks were reviewed. Patients were given either 500 mg b.i.d. throughout the treatment period [Group 1 (n=41)], 500 mg b.i.d. for 3 weeks and then 750 mg q.d. [Group 2 (n=21)] or 750 mg q.d. for the whole treatment period [Group 3 (n=22)]. All patients had combined therapy, including levofloxacin-rifampin in 62 cases (73.8%), for an average duration of 13.7 weeks. Muscular pain and/or tendonitis were reported in 19 patients (22.6%) which affected more patients in Groups 1 and 2 than in Group 3 (14/41 and 5/21 vs. 0/22; p=0.01 and 0.001, respectively). A dosage of 750 mg q.d. may be warranted for prolonged high-dose levofloxacin treatment in patients with bone infections rather than 500 mg b.i.d. for the entire duration of treatment, or for the first 3 weeks.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18230552     DOI: 10.1179/joc.2007.19.6.688

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis.

Authors:  David P Holland; Gillian D Sanders; Carol D Hamilton; Jason E Stout
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

2.  Oral Antibiotic Management of Acute Osteomyelitis of the Hand: Outcomes and Cost Comparison to Standard Intravenous Regimen.

Authors:  Mark Henry; Forrest H Lundy
Journal:  Hand (N Y)       Date:  2019-09-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.